PURPOSE: The neoplastic Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL) are derived from B cells. The frequency of HLA class II downregulation and its effect on prognosis are unknown. PATIENTS AND METHODS: Immunohistochemistry results for HLA class II were evaluated in 292 primary cHL patients in a population-based approach. Patients were diagnosed between 1989 and 2000 in the northern part of the Netherlands. Median age at diagnosis was 38 years (range, 8 to 88 years); 63% had Ann Arbor stage I or II, 24% stage III, and 13% stage IV disease. Median follow-up was 7.1 years. For 168 patients, HLA genotype data were available. RESULTS: Lack of HLA class II cell-surface expression on HRS cells was observed in 41.4% and was more common in patients with extranodal disease, patients with Epstein-Barr virus-negative disease, and patients with HLA class I-negative HRS cells. Alleles of three microsatellite markers in the HLA class II region were associated with presence or absence of protein expression. In univariate analyses, lack of HLA class II expression coincided with adverse outcome (5-years failure free survival [FFS], 67% v 85%; P = .001; 5-years age and sex matched relative survival (RS), 80% v 90%; P = .027). This effect remained in multivariate analyses for FFS with a hazard ratio of 2.40 (95% CI, 1.45 to 3.98) and RS with a relative excess risk of death of 2.55 (95% CI, 1.22 to 5.31). CONCLUSION: Lack of membranous HLA class II expression by HRS cells in diagnostic lymph node specimens is an independent adverse prognostic factor in cHL.
PURPOSE: The neoplastic Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL) are derived from B cells. The frequency of HLA class II downregulation and its effect on prognosis are unknown. PATIENTS AND METHODS: Immunohistochemistry results for HLA class II were evaluated in 292 primary cHL patients in a population-based approach. Patients were diagnosed between 1989 and 2000 in the northern part of the Netherlands. Median age at diagnosis was 38 years (range, 8 to 88 years); 63% had Ann Arbor stage I or II, 24% stage III, and 13% stage IV disease. Median follow-up was 7.1 years. For 168 patients, HLA genotype data were available. RESULTS: Lack of HLA class II cell-surface expression on HRS cells was observed in 41.4% and was more common in patients with extranodal disease, patients with Epstein-Barr virus-negative disease, and patients with HLA class I-negative HRS cells. Alleles of three microsatellite markers in the HLA class II region were associated with presence or absence of protein expression. In univariate analyses, lack of HLA class II expression coincided with adverse outcome (5-years failure free survival [FFS], 67% v 85%; P = .001; 5-years age and sex matched relative survival (RS), 80% v 90%; P = .027). This effect remained in multivariate analyses for FFS with a hazard ratio of 2.40 (95% CI, 1.45 to 3.98) and RS with a relative excess risk of death of 2.55 (95% CI, 1.22 to 5.31). CONCLUSION: Lack of membranous HLA class II expression by HRS cells in diagnostic lymph node specimens is an independent adverse prognostic factor in cHL.
Authors: Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza Journal: Blood Date: 2011-12-13 Impact factor: 22.113
Authors: C F Skibola; N K Akers; L Conde; M Ladner; S K Hawbecker; F Cohen; F Ribas; H A Erlich; D Goodridge; E A Trachtenberg; M T Smith; P M Bracci Journal: Tissue Antigens Date: 2012-02-02
Authors: Soham D Puvvada; Hongli Li; Lisa M Rimsza; Steven H Bernstein; Richard I Fisher; Michael LeBlanc; Monika Schmelz; Betty Glinsmann-Gibson; Thomas P Miller; Anne-Marie Maddox; Jonathan W Friedberg; Sonali M Smith; Daniel O Persky Journal: Leuk Lymphoma Date: 2016-01-12
Authors: Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang Journal: Cancer Immunol Res Date: 2019-06-24 Impact factor: 11.151
Authors: Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Christian Steidl; Sohrab P Shah; Bruce W Woolcock; Lixin Rui; Masahiro Kawahara; Pedro Farinha; Nathalie A Johnson; Yongjun Zhao; Adele Telenius; Susana Ben Neriah; Andrew McPherson; Barbara Meissner; Ujunwa C Okoye; Arjan Diepstra; Anke van den Berg; Mark Sun; Gillian Leung; Steven J Jones; Joseph M Connors; David G Huntsman; Kerry J Savage; Lisa M Rimsza; Douglas E Horsman; Louis M Staudt; Ulrich Steidl; Marco A Marra; Randy D Gascoyne Journal: Nature Date: 2011-03-02 Impact factor: 49.962
Authors: Samantha Kendrick; Lisa M Rimsza; David W Scott; Graham W Slack; Pedro Farinha; King L Tan; Daniel Persky; Soham Puvvada; Joseph M Connors; Laurie Sehn; Randy D Gascoyne; Monika Schmelz Journal: Virchows Arch Date: 2016-11-25 Impact factor: 4.064
Authors: Margaretha G M Roemer; Robert A Redd; Fathima Zumla Cader; Christine J Pak; Sara Abdelrahman; Jing Ouyang; Stephanie Sasse; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Stephen Ansell; Kazunobu Kato; Benedetto Farsaci; Anne Sumbul; Philippe Armand; Donna S Neuberg; Geraldine S Pinkus; Azra H Ligon; Scott J Rodig; Margaret A Shipp Journal: J Clin Oncol Date: 2018-02-02 Impact factor: 44.544